ZLAB
ZLAB clinical trials: Zai Lab Ltd
Every trial on ClinicalTrials.gov where Zai Lab Ltd is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 11
- Trials linked
- 2
- As lead sponsor
- 9
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ZLAB on the catalyst calendar · ZLAB registry changes
- Primary completion May 25, 2018ActualPhase 2NCT03134352Study to Evaluate the Efficacy and Safety of ZL-3101 in Subjects With Subacute EczemaZai Lab Pty. Ltd. · EczemaCompletedZLABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2016ActualPhase 1NCT02397005Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male SubjectsZai Lab Pty. Ltd. · Chronic Obstructive Pulmonary DiseaseUnknown statusZLABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2028Sponsor estimatePhase 1NCT07374848Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected TumorsZai Lab (Shanghai) Co., Ltd. · Solid TumorsRecruitingZLABCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 26, 2030Sponsor estimatePhase 1/Phase 2NCT07707895DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other...Boehringer Ingelheim · Small Cell Lung CancerRecruitingZLABCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 20, 2025ActualPhase 3NCT05052801Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionAmgen · Gastric CancerCompletedAMGNLeadZLABCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2028Sponsor estimatePhase 3NCT07218146A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)Zai Lab (Shanghai) Co., Ltd. · Small-cell Lung CancerRecruitingZLABCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 30, 2027Sponsor estimatePhase 1NCT06179069A Study of ZL-1310 in Subjects With Small Cell Lung CancerZai Lab (Shanghai) Co., Ltd. · SCLCRecruitingZLABCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2030Sponsor estimatePhase 3NCT07796100A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint...Zai Lab (Shanghai) Co., Ltd. · Extensive-Stage Small Cell Lung CancerNot yet recruitingZLABCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 1/Phase 2NCT06885281A Study of ZL-1310 in Participants With Selected Solid TumorsZai Lab (Shanghai) Co., Ltd. · Solid TumorsRecruitingZLABCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 16, 2025ActualPhase 2NCT06380907A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque PsoriasisZai Lab (Hong Kong), Ltd. · Plaque PsoriasisTerminatedZLABCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 5, 2024ActualPhase 2NCT05810961A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)argenx · Membranous NephropathyTerminatedARGXLeadZLABCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner